Europlasma (France) Probability of Future Stock Price Finishing Over 10.24

ALEUP Stock  EUR 0.12  0.06  95.12%   
Europlasma's future price is the expected price of Europlasma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Europlasma SA performance during a given time horizon utilizing its historical volatility. Check out Europlasma Backtesting, Europlasma Valuation, Europlasma Correlation, Europlasma Hype Analysis, Europlasma Volatility, Europlasma History as well as Europlasma Performance.
  
Please specify Europlasma's target price for which you would like Europlasma odds to be computed.

Europlasma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Europlasma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Europlasma SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Europlasma SA is way too risky over 90 days horizon
Europlasma SA has some characteristics of a very speculative penny stock
Europlasma SA appears to be risky and price may revert if volatility continues
Europlasma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
Europlasma SA has accumulated 2.92 M in total debt with debt to equity ratio (D/E) of 769.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Europlasma SA has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Europlasma until it has trouble settling it off, either with new capital or with free cash flow. So, Europlasma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Europlasma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Europlasma to invest in growth at high rates of return. When we think about Europlasma's use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 9.8 M. Net Loss for the year was (12.67 M) with profit before overhead, payroll, taxes, and interest of 5.65 M.
Europlasma SA has accumulated about 3.92 M in cash with (18.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.

Europlasma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Europlasma Stock often depends not only on the future outlook of the current and potential Europlasma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Europlasma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding12.9 T
Cash And Short Term Investments2.5 M

Europlasma Technical Analysis

Europlasma's future price can be derived by breaking down and analyzing its technical indicators over time. Europlasma Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Europlasma SA. In general, you should focus on analyzing Europlasma Stock price patterns and their correlations with different microeconomic environments and drivers.

Europlasma Predictive Forecast Models

Europlasma's time-series forecasting models is one of many Europlasma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Europlasma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Europlasma SA

Checking the ongoing alerts about Europlasma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Europlasma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Europlasma SA is way too risky over 90 days horizon
Europlasma SA has some characteristics of a very speculative penny stock
Europlasma SA appears to be risky and price may revert if volatility continues
Europlasma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
Europlasma SA has accumulated 2.92 M in total debt with debt to equity ratio (D/E) of 769.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Europlasma SA has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Europlasma until it has trouble settling it off, either with new capital or with free cash flow. So, Europlasma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Europlasma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Europlasma to invest in growth at high rates of return. When we think about Europlasma's use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 9.8 M. Net Loss for the year was (12.67 M) with profit before overhead, payroll, taxes, and interest of 5.65 M.
Europlasma SA has accumulated about 3.92 M in cash with (18.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.

Additional Tools for Europlasma Stock Analysis

When running Europlasma's price analysis, check to measure Europlasma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Europlasma is operating at the current time. Most of Europlasma's value examination focuses on studying past and present price action to predict the probability of Europlasma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Europlasma's price. Additionally, you may evaluate how the addition of Europlasma to your portfolios can decrease your overall portfolio volatility.